Anti-VEGFtherapyforneovascularoculardiseasesCiullaandRosenfeld169
andsigni cantlyincreasedmeanvisualacuitybyþ5.1lettersat12months(P<0.05)[55].
Aretrospectivemulticenterstudyof78eyesfrom64patientswithDMEfromsixSouthAmericancountriesdemonstratedthatintravitrealbevacizumabatdosesof1.25to2.5mgappearstoprovidestabilityorimprove-mentinvisualacuity,andinOCTand uoresceinangio-graphyresultsat6months.Themeanbest-correctedvisualacuity(BCVA)was0.87andthe nalmeanBCVAwas0.6(P<0.0001).Inthe nalBCVAsubgroupanalysis,41%(32/78)ofeyesremainedstable,55%(43/78)gainedatleasttwoearlytreatmentofdiabeticretinopathystudy(ETDRS)lines,and3.8%(3/78)lostatleasttwoETDRSlinesofBCVA.OCTshowedadecreaseinmeanCMTfrom387.0Æ182.8mmatbase-lineto275.7Æ108.3mmatendoffollow-up(P<0.0001)[56 ].Thesearepromisingresults,althoughlongerfol-low-upstudiesarestillrequired.
InanotherphaseIIstudy,121eyesfrom121patientswererandomizedto vetreatmentgroups:groupA,focalphotocoagulationatbaseline(n¼19);groupB,1.25mgintravitrealbevacizumabatbaselineand6weeks(n¼22);groupC,2.5mgintravitrealbevacizumabatbaselineand6weeks(n¼24);groupD,1.25mgintra-vitrealbevacizumabatbaselineandshaminjectionat6weeks(n¼22);orgroupE,1.25mgintravitrealbev-acizumabatbaselineand6weekswithphotocoagulationat3weeks(n¼22)[57 ].Centralsub eldthickness(CST)byOCTandBCVAweremeasuredatbaselineandat3,6,9,12,18,and24weeks.GroupsBandC(bevacizumabaloneatbaselineand4or6weeks)hadagreaterreductioninCSTat3weeksandhadaboutonelineimprovementinmedianBCVAover12weeks,withnomeaningfuldifferencesineitherparameterbetweenthetwogroups.ACSTreductiongreaterthanthereliabilitylimitof11%wasseenat3weeksin43%(36/84)ofbevacizumab-treatedeyesandin28%(5/18)ofeyestreatedwithlaseralone,andat6weeksin37%(31/84)and50%(9/18)ofeyes,respectively.Therewasnoappar-entshort-termbene toradverseeffectfromcombiningfocalphotocoagulationwithbevacizumab[57 ].PhaseIIIrandomized,controlledstudiesofintravitrealbevacizumab,aloneorincombinationwithtriamcinoloneacetonideandlaserphotocoagulation,inthetreatmentofDMEarecurrentlyinprogress.
Withtheincreaseduseofintravitrealbevacizumab,afewcasesofuveitisassociatedwiththistreatmenthavebeenreported[58];however,uveitiswasreportedwiththeuseofranibizumabaswell[59,60].Thereisalwaysaneedforcautiousawarenessofitspotentialforcausingintraocularin ammation.Additionally,becauserepeatedlong-termintravitrealdosesofanti-VEGFagentscan ndtheirway
intothecirculation,itisimportanttomonitorforpoten-tialsystemiceffects,particularlythoseofconcernindiabeticpatients;however,nonehasbeenreported.Theseadverseeventsincludehypertension,proteinuria,impairedwoundhealing,impairedcollateralvesseldevelopment,inhibitionofbonegrowth,skeletalmuscleregeneration,cardiacremodeling,andinfertility[61].AphaseIIrandomized,double-maskedsafetyandpre-liminaryef cacyclinicaltrialofthesiRNAbevasiranibinDMEwasrecentlycompleted,althoughdatahavenotyetbeenreported.PromisingresultsfromaphaseIstudyofVEGFtrapevaluating vepatientswithDMEshowedthatafterreceivingasingleintravitrealdose(4.0mg)ofVEGFtrap,fourof vepatientshadimprovementsinBCVAofsixto10lettersat4weekspostinjection,withameandecreaseincentralretinalthicknessof115mm[61,62].
AlthoughpatientswithPDRarehighlysensitivetoanti-VEGFtreatments,somepatientswithretinaledemashowonlypartialresponsesandmayrequirehigherdoses,suggestingthatotherVEGF-independentmechanismsmaybeinvolvedinedemaandrequiredifferentthera-peuticapproaches[63 ].Antiangiogeniccorticosteroidswereconsideredaspotentialtreatmentforchoroidalneovascularization(CNV)inhumansaftertriamcinoloneacetonidewasshowntoinhibit brovascularproliferationandneovascularizationinlaser-treatedratmodelchoroi-dalneovascularmembranes[64].RecentreportsimplythatresolutionofedemaandimprovementsinvisualacuityinpatientswithDMEmaybebetterassociatedwithananti-in ammatory,ratherthanantiangiogenic,effectofcorticosteroids[65,66 ,67].Inthisdirection,aphaseItrialtoevaluatethecombinationofranibizumabandtheanti-in ammatoryagent,efalizumab,forthetreatmentofDME[CombinedAPproachtoTreatmentUsingRanibizumabandEfalizumabforDiabeticMacu-larEdema(CAPTUREDME)study]isunderway.Like-wise,acomparisonstudyofintravitrealranibizumabortriamcinolone,aloneorincombinationwithlasertreat-mentforDME(LRTforDME),hasrecentlybegun(doc.guandang.net).
Triamcinoloneacetonideanddexamethasonearecur-rentlyundergoingearlyclinicalinvestigationinDME.One3-yearprospective,randomized,double-maskedmulticenterstudyoftriamcinoloneacetonideinDMEisassessingthesafetyandtolerabilityofsustaineddrugdeliverythroughintravitrealimplants[68].ThereareseveralcurrentphaseIIIstudiesoftriamcinoloneacet-onideinDME.AlsoongoingarephaseIIItrialsevaluat-ingdexamethasoneinDMEandRVOand uocinoloneinDME.Relatedantiangiogeniccorticosteroidagentsinsustained-releasedforms,suchasthedexamethasoneimplantandthe uocinoloneimplant,haveshown
therapy for advanced or metastatic colorectal cancer: National Comprehensive Cancer Network guidelines for combining anti-vascular endothelial growth factor and ...
anti-vascular endothelial growth factor (VEGF) ...found in human plasma and serum and ocular ...(Avastin) therapy for neovascular age-related ...
anti-vascular endothelial growth factor therapy – bevacizumab Acta Ophthalmol....It has been known that ocular diseases in which in?ammatory and autoimmune...
therapy or having an accompanying ocular disease. ...therapy for neovascular age - related macular ... an anti-vascular endothelial growth factor antigen...
(Macugen ) TM 1 The Impact of Neovascular AMD ...Injection – First Anti-VEGF Therapy for the Eye...Vascular Endothelial Growth Factor (VEGF) Vascular ...
anti-vascular endothelial growth factor fusion ...Thus, with one injection of KH902, neovascular ...Both of them could inhibit the ocular ...
anti-vascular endothelial growth factor fusion ...Thus, with one injection of KH902, neovascular ...Both of them could inhibit the ocular ...
热门文档